Acrivon Therapeutics, Inc. Common Stock (ACRV) vs Pulmonx Corporation (LUNG)
A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and Pulmonx Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.89HealthcareDelayed quote: Oct 6, 2026, 2:44 PM EDT
LUNG
Pulmonx Corporation
$1.80HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Total return — ACRV vs LUNG
growth of $100 · dividends reinvested · last 4yACRV -88.1% (-41.3%/yr)LUNG -67.7% (-24.6%/yr)LUNG compounded faster over this window
ACRV LUNG
ACRV vs LUNG: by the numbers
- •ACRV is the larger company ($81M vs $76M market cap).
- •Both run net losses; ACRV's is the smaller (0.00% vs -55.03% net margin).
Metrics side by side
Valuation
| Metric | ACRV | LUNG |
|---|---|---|
| P/S ratio | N/A | 0.87 |
| P/B ratio | 0.93 | 1.93 |
Profitability
| Metric | ACRV | LUNG |
|---|---|---|
| Gross margin | 0.00% | 77.06% |
| Operating margin | 0.00% | -52.96% |
| Net margin | 0.00% | -55.03% |
| ROE | -85.65% | -122.76% |
| ROIC | -88.28% | -48.39% |
Growth (annualized)
| Metric | ACRV | LUNG |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 15.86% |
| Total return CAGR (5Y) | N/A | -45.30% |
Go deeper
Dig into the metrics
Acrivon Therapeutics, Inc. Common Stock ROEPulmonx ROEAcrivon Therapeutics, Inc. Common Stock operating marginPulmonx operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthPulmonx revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowPulmonx free cash flow
Acrivon Therapeutics, Inc. Common Stock & Pulmonx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.